MicroRNAS - new promising tumor biological markers and targets for chemotherapy. Part 3. therapeutic use of microRNA. Methods of measuring microRNA concentration

A.N. Shirshova; M.A. Smetanina; V.N. Aushev; M.L. Filipenko; N.E. Kushlinskii

MicroRNAS - new promising tumor biological markers and targets for chemotherapy. Part 3. therapeutic use of microRNA. Methods of measuring microRNA concentration

A.N. Shirshova¹, M.A. Smetanina², V.N. Aushev³, M.L. Filipenko⁴, N.E. Kushlinskii⁵

research article Pages: 31-39

¹ Researcher, Laboratory of Pharmacogenomics, Institute of Сhemical Biology and Fundamental Medicine Siberian Branch of the Russian Academy of Sciences (ICBFM SB RAS), Novosibirsk
² Ph.D.(Biol.), Researcher, Laboratory of Pharmacogenomics, Institute of Chemical Biology and Fundamental Medicine Siberian Branch of the Russian Academy of Sciences (ICBFM SB RAS), Novosibirsk
³ Ph.D.(Med.), Senior Researcher, Laboratory of Oncogenes Regulation, Carcinogenesis Institute, N.N. Blokhin Russian Cancer Research Center, Moscow
⁴ Ph.D.(Biol.), Head of the Laboratory of Pharmacogenomics, Institute of Chemical Biology and Fundamental Medicine Siberian Branch of the Russian Academy of Sciences, Novosibirsk
⁵ Dr.Sc. (Med.), Professor, Head of the Clinical Biochemistry Laboratory, N.N. Blokhin Russian Cancer Research Center, Moscow

Keywords: microRNA treatment detection methods

Abstract

The data on the treatment of various diseases with the help of microRNAs and contemporary methods of microRNA concentrations measurement in biological fluids by means of real-time PCR technologies are reviewed. Examples of the application of primers from different manufacturers are shown.

How to cite

Ширшова А.Н., Сметанина М.А., Аушев В.Н., Филипенко М.Л., Кушлинский Н.Е. МикроРНК - новые перспективные биомаркеры опухолей и мишени химиотерапии. Часть 3. Терапевтическое применение микроРНК. Методы количественного определения // Вопросы биологической, медицинской и фармацевтической химии. 2015. № 4. С. 31–39.

References

Ishida M., Selaru F.M. miRNA-Based Therapeutic Strategies // Curr. Anesthesiol. Rep. 2013. V. 1. № 1. P. 63 - 70.
Baker B.F., Lot S.S., Condon T.P. et al. 2\'-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells // J. Biol. Chem. 1997. V. 272. № 18. P. 11994 - 12000.
Si M.L., Zhu S., Wu H. et al. miR-21-mediated tumor growth // Oncogene. 2007. V. 26. № 19. P. 2799 - 2803.
Weiler J., Hunziker J., Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease - // Gene Ther. 2006. V. 13. № 6. P. 496 - 502.
Krützfeld J., Rajewsky N., Braich R. et al. Silencing of microRNAs in vivo with "antagomirs" // Nature. 2005. V. 438. № 7068. P. 685 - 689.
Ebert M.S., Neilson J.R., Sharp P.A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells // Nat. Methods. 2007. V. 4. № 9. P. 721 - 726.
Gumireddy K., Young D.D., Xiong X. et al. Small-molecule inhibitors of microrna miR-21 function // Angew. Chem. Int. Ed. Engl. 2008. V. 47. № 39. P. 7482 - 7484.
Koshkin A., Singh S.K., Nielsen P. et al. LNA: synthesis of the adenine, cytosine, guanine 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation and unprecedented nucleic acid recognition // Tetrahedron. 1998. V. 54. P. 3607 - 3630.
Lindow M., Kauppinen S. Discovering the first microRNA-targeted drug // J. Cell Biol. 2012. V. 199. № 3. P. 407 - 412.
Janssen H.L., Reesink H.W., Lawitz E.J. et al. Treatment of HCV infection by targeting microRNA // N. Engl. J. Med. 2013. V. 368. № 18. P. 1685 - 1694.
Qiu Z., Dai Y. Roadmap of miR-122-related clinical application from bench to bedside // Expert. Opin. Investig. Drugs. 2014. V. 23. № 3. P. 347 - 355.
Jiang J., Zheng X., Xu X. et al. Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin // PLoS One. 2011. V. 6. № 8. e23271.
Stegmeier F., Hu G., Rickles R.J. et al. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells // Proc. Natl. Acad. Sci. USA. 2005. V. 102. № 37. P. 13212 - 13217.
Chung K.H., Hart C.C., Al-Bassam S. et al. Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155 // Nucleic Acids Res. 2006. V. 34. № 7. P. e53.
Kota J., Chivukula R.R., O\'donnell K.A. et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model // Cell. 2009. V. 137. № 6. P. 1005 - 1017.
Tsai K.W., Wu C.W., Hu L.Y. et al. Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer // Int. J. Cancer. 2011. V. 129. № 11. P. 2600 - 2610.
Xia L., Zhang D., Du R. et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells // Int. J. Cancer. 2008. V. 123. № 2. P. 372 - 379.
Scholl V., Hassan R., Zalcberg I.R. miRNA-451: A putative predictor marker of Imatinib therapy response in chronic myeloid leukemia // Leuk. Res. 2012. V. 36. № 1. P. 119 - 121.
Bai S., Nasser M.W., Wang B. et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib // J. Biol. Chem. 2009. V. 284. № 46. P. 32015 - 32027.
Ling H., Fabbri M., Calin G.A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nature reviews // Nat. Rev. Drug Discov. 2013. V. 12. № 11. P. 847 - 865.
Di Martino M.T., Campani V., Misso G. et al.In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma // PloS one. 2014. V. 9. № 2. P. e90005.
Velu C.S., Chaubey A., Phelan J.D. et al. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity // J. Clin. Invest. 2014. V. 124. № 1. P. 222 - 236.
Huang X., Schwind S., Yu B. et al. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia // Clin. Cancer Res. 2013. V. 19. № 9. P. 2355 - 2367.
Gong J.N., Yu J., Lin H.S. et al. The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia // Cell Death Differ. 2014. V. 21. № 1. P. 100 - 112.
Ito M., Teshima K., Ikeda S. et al. MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6 in advanced cutaneous T-cell lymphoma // Blood. 2014. V. 123. № 10. P. 1499 - 1511.
Chen C., Ridzon D.A., Broomer A.J. et al. Real-time quantification of microRNAs by stem-loop RT-PCR // Nucleic Acids Res. 2005. V. 33. № 20. P. e179.
Mestdagh P., Feys T., Bernard N. et al. High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA // Nucleic Acids Res. 2008. V. 36. № 21. P. e143.
Yang H., Schmuke J.J., Flagg L.M. et al. A novel real-time polymerase chain reaction method for high through put quantification of small regulatory RNAs // Plant. Biotechnol. J. 2009. V. 7. № 7. P. 621 - 630.
Hildebrand J., Grundhoff A., Gallinat S. et al. MicroRNA profiling during human keratinocyte differentiation using a quantitative real-time PCR method // Methods Mol. Biol. 2013. V. 961. P. 193 - 200.
Sharbati-Tehrani S., Kutz-Lohroff B., Bergbauer R. et al. miR-Q: a novel quantitative RT-PCR approach for the expression profiling of small RNA molecules such as miRNAs in a complex sample // BMC Mol. Biol. 2008. V. 10. P. 9 - 34.
Shi R., Chiang V.L. Facile means for quantifying microRNA expression by real-time PCR // Biotechniques. 2005. V. 39. № 4. P. 519 - 525.
Shi R., Sun Y.H., Zhang X.H., Chiang V.L. Poly(T) adaptor RT-PCR // Methods Mol. Biol. 2012. V. 822. P. 53 - 66.
Mohammadi-Yeganeh S., Paryan M., Mirab Samiee S. et al. Development of a robust, low cost stem-loop real-time quantification PCR technique for miRNA expression analysis // Mol. Biol. Rep. 2013. V. 40. № 5. P. 3665 - 3674.

[1] Ishida M., Selaru F.M. miRNA-Based Therapeutic Strategies // Curr. Anesthesiol. Rep. 2013. V. 1. № 1. P. 63 - 70.

[2] Baker B.F., Lot S.S., Condon T.P. et al. 2\'-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells // J. Biol. Chem. 1997. V. 272. № 18. P. 11994 - 12000.

[3] Si M.L., Zhu S., Wu H. et al. miR-21-mediated tumor growth // Oncogene. 2007. V. 26. № 19. P. 2799 - 2803.

[4] Weiler J., Hunziker J., Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease - // Gene Ther. 2006. V. 13. № 6. P. 496 - 502.

[5] Krützfeld J., Rajewsky N., Braich R. et al. Silencing of microRNAs in vivo with "antagomirs" // Nature. 2005. V. 438. № 7068. P. 685 - 689.

[6] Ebert M.S., Neilson J.R., Sharp P.A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells // Nat. Methods. 2007. V. 4. № 9. P. 721 - 726.

[7] Gumireddy K., Young D.D., Xiong X. et al. Small-molecule inhibitors of microrna miR-21 function // Angew. Chem. Int. Ed. Engl. 2008. V. 47. № 39. P. 7482 - 7484.

[8] Koshkin A., Singh S.K., Nielsen P. et al. LNA: synthesis of the adenine, cytosine, guanine 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation and unprecedented nucleic acid recognition // Tetrahedron. 1998. V. 54. P. 3607 - 3630.

[9] Lindow M., Kauppinen S. Discovering the first microRNA-targeted drug // J. Cell Biol. 2012. V. 199. № 3. P. 407 - 412.

[10] Janssen H.L., Reesink H.W., Lawitz E.J. et al. Treatment of HCV infection by targeting microRNA // N. Engl. J. Med. 2013. V. 368. № 18. P. 1685 - 1694.

[11] Qiu Z., Dai Y. Roadmap of miR-122-related clinical application from bench to bedside // Expert. Opin. Investig. Drugs. 2014. V. 23. № 3. P. 347 - 355.

[12] Jiang J., Zheng X., Xu X. et al. Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin // PLoS One. 2011. V. 6. № 8. e23271.

[13] Stegmeier F., Hu G., Rickles R.J. et al. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells // Proc. Natl. Acad. Sci. USA. 2005. V. 102. № 37. P. 13212 - 13217.

[14] Chung K.H., Hart C.C., Al-Bassam S. et al. Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155 // Nucleic Acids Res. 2006. V. 34. № 7. P. e53.

[15] Kota J., Chivukula R.R., O\'donnell K.A. et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model // Cell. 2009. V. 137. № 6. P. 1005 - 1017.

[16] Tsai K.W., Wu C.W., Hu L.Y. et al. Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer // Int. J. Cancer. 2011. V. 129. № 11. P. 2600 - 2610.

[17] Xia L., Zhang D., Du R. et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells // Int. J. Cancer. 2008. V. 123. № 2. P. 372 - 379.

[18] Scholl V., Hassan R., Zalcberg I.R. miRNA-451: A putative predictor marker of Imatinib therapy response in chronic myeloid leukemia // Leuk. Res. 2012. V. 36. № 1. P. 119 - 121.

[19] Bai S., Nasser M.W., Wang B. et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib // J. Biol. Chem. 2009. V. 284. № 46. P. 32015 - 32027.

[20] Ling H., Fabbri M., Calin G.A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nature reviews // Nat. Rev. Drug Discov. 2013. V. 12. № 11. P. 847 - 865.

[21] Di Martino M.T., Campani V., Misso G. et al.In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma // PloS one. 2014. V. 9. № 2. P. e90005.

[22] Velu C.S., Chaubey A., Phelan J.D. et al. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity // J. Clin. Invest. 2014. V. 124. № 1. P. 222 - 236.

[23] Huang X., Schwind S., Yu B. et al. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia // Clin. Cancer Res. 2013. V. 19. № 9. P. 2355 - 2367.

[24] Gong J.N., Yu J., Lin H.S. et al. The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia // Cell Death Differ. 2014. V. 21. № 1. P. 100 - 112.

[25] Ito M., Teshima K., Ikeda S. et al. MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6 in advanced cutaneous T-cell lymphoma // Blood. 2014. V. 123. № 10. P. 1499 - 1511.

[26] Chen C., Ridzon D.A., Broomer A.J. et al. Real-time quantification of microRNAs by stem-loop RT-PCR // Nucleic Acids Res. 2005. V. 33. № 20. P. e179.

[27] Mestdagh P., Feys T., Bernard N. et al. High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA // Nucleic Acids Res. 2008. V. 36. № 21. P. e143.

[28] Yang H., Schmuke J.J., Flagg L.M. et al. A novel real-time polymerase chain reaction method for high through put quantification of small regulatory RNAs // Plant. Biotechnol. J. 2009. V. 7. № 7. P. 621 - 630.

[29] Hildebrand J., Grundhoff A., Gallinat S. et al. MicroRNA profiling during human keratinocyte differentiation using a quantitative real-time PCR method // Methods Mol. Biol. 2013. V. 961. P. 193 - 200.

[30] Sharbati-Tehrani S., Kutz-Lohroff B., Bergbauer R. et al. miR-Q: a novel quantitative RT-PCR approach for the expression profiling of small RNA molecules such as miRNAs in a complex sample // BMC Mol. Biol. 2008. V. 10. P. 9 - 34.

[31] Shi R., Chiang V.L. Facile means for quantifying microRNA expression by real-time PCR // Biotechniques. 2005. V. 39. № 4. P. 519 - 525.

[32] Shi R., Sun Y.H., Zhang X.H., Chiang V.L. Poly(T) adaptor RT-PCR // Methods Mol. Biol. 2012. V. 822. P. 53 - 66.

[33] Mohammadi-Yeganeh S., Paryan M., Mirab Samiee S. et al. Development of a robust, low cost stem-loop real-time quantification PCR technique for miRNA expression analysis // Mol. Biol. Rep. 2013. V. 40. № 5. P. 3665 - 3674.

Abstract

How to cite

Related articles